Circulating tumour cells are a prognostic indicator in advanced high-grade serous ovarian cancer and are associated with platelets and immune cells following dissemination

DDRi Summit 2025: Monitoring of DNA Damage Response Biomarkers using Circulating Tumour Cells captured with ANGLE’s Parsortix® instrument from Ovarian, Prostate, and Breast cancer patients

DDR Conference – Detection of DNA Damage Response Biomarkers in Circulating Tumour Cells using ANGLE’s Parsortix® instrument and downstream immunofluorescence assays

Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium

Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy

Malignancy Assessment Using Gene Identification in Captured Cells Algorithm for the Prediction of Malignancy in Women With a Pelvic Mass

Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients

Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells